Monopar Therapeutics
MNPR
13 hedge funds and large institutions have $1.21M invested in Monopar Therapeutics in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and closing their positions.
181% more capital invested
Capital invested by funds: $429K → $1.21M (+$778K)
86% more funds holding
Funds holding: 7 → 13 (+6)
0.19% more ownership
Funds ownership: 0.12% → 0.31% (+0.19%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$348K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$329K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$193K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$91.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$66.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$166K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Marshall Wace
London,
United Kingdom
| $295K | +$348K | +9,531 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $279K | +$329K | +9,014 | New |
|
|
3
Northern Trust
Chicago,
Illinois
| $223K | -$166K | -4,559 | -39% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $163K | +$193K | +5,279 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $77K | +$91.1K | +2,496 | New |
|
6
BlackRock
New York
| $70K | +$42.6K | +1,168 | +108% |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $57K | +$66.7K | +1,826 | New |
|
8
Morgan Stanley
New York
| $20K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $14K | +$5.88K | +161 | +57% |
|
|
APA
10
American Portfolios Advisors
Holbrook,
New York
| $4.34K | +$5.11K | +140 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $4K | -$2.77K | -76 | -40% |
|
12
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
MNPR Hedge Fund Activity: Q1 2021 in Review
13 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2021, worth a combined $1.21M — up 181% from $429K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MNPR positions and 0 closed out — a net gain of 6 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $348K. The largest seller was Northern Trust, cutting an estimated $166K.
- 13 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2021, up from 7 in Q4 2020.
- Funds reported $1.21M of Monopar Therapeutics stock for Q1 2021, up 181% quarter-over-quarter.
- 6 funds opened new Monopar Therapeutics positions in Q1 2021 and 0 closed out, a net change of +6 holders.
- The largest Monopar Therapeutics buyer in Q1 2021 was Marshall Wace, an estimated $348K added.
- The largest Monopar Therapeutics seller in Q1 2021 was Northern Trust, an estimated $166K sold.
Based on aggregated 13F filings for Q1 2021.